Latest research findings: androgen deprivation therapy or male novel coronavirus patients "salvation

Today, novel coronavirus pneumonia research team led by Andrea Alimonti, Switzerland, published a weightier study. By analyzing data on all cancer patients in Venetian, Italy, it was discovered that androgen deprivation therapy might reduce the risk of male infection with novel coronavirus (COVID-19,SARS-CoV-2) pneumonia.

Specifically, novel coronavirus pneumonia patients novel coronavirus pneumonia patients who received androgen deprivation therapy were 4 times less likely to develop new prostate cancer than those who did not receive androgen deprivation therapy. Compared with those of other types of cancer, the risk of new coronavirus pneumonia in patients receiving androgen deprivation therapy was 5 times lower.

This study first reveals novel coronavirus pneumonia and novel coronavirus (COVID-19,SARS-CoV-2) pneumonia infection. Relevant research results were published in the annals of oncology, the international top clinical oncology journal.

Novel coronavirus pneumonia and the Wuhan Union Hospital affiliated to Huazhong University of Science and Technology in Beijing had found that the risk of death was significantly higher than that of women, which was 2.5 times that of women.

Differences in the proportion of male and female deaths in novel coronavirus (COVID-19,SARS-CoV-2) patients in different countries

At that time, some scholars said that this may be related to hormones, because the hormone estrogen in women's body has an impact on the immune system. Estrogen can stimulate the production of interferon to enhance the human body's immunity, so as to help the human body eliminate the virus.

Based on this study, some doctors in New York have begun to use estrogen to treat male patients with new coronavirus to enhance their immunity. In addition, some doctors in Los Angeles will also start to use another hormone mainly existing in women, namely progesterone, to treat male patients. Progesterone has an anti-inflammatory effect and may prevent the immune system from producing harmful overreaction.

Androgen and risk of new coronavirus infection

Novel coronavirus pneumonia was first studied by Professor Alimonti early in the year, and his colleagues began to study the effects of hormones on the infection of novel coronavirus (COVID-19,SARS-CoV-2) pneumonia.

Androgen deprivation therapy is a treatment for prostate cancer patients. Studies have shown that novel coronavirus pneumonia virus can infect healthy human cells, a protein called TMPRSS2. TMPRSS2 is a member of the type II transmembrane serine protease protein family, which is involved in many human processes, including cancer and virus infection.

The level of TMPRSS2 in prostate cancer patients is very high, and its effect is mainly regulated by androgen receptor, which is the target of a series of androgen deprivation therapy. Androgen receptors also regulate the level of TMPRSS2 in the tissue of febph, including the lung.

Novel coronavirus pneumonia may be associated with infection with novel coronavirus (COVID-19,SARS-CoV-2) pneumonia, Professor Alimonti suspects.

What novel coronavirus pneumonia novel coronavirus pneumonia novel coronavirus pneumonia patients were collected from the data of all the new cancer patients in Italy, and then found that even though the risk of novel coronavirus (COVID-19,SARS-CoV-2) pneumonia was higher in cancer patients, the patients who had received androgen deprivation therapy seemed to be protected by new infections. They even had a novel coronavirus (COVID-19,SARS-CoV-2). The risk of pneumonia was significantly reduced.

Specifically, novel coronavirus pneumonia novel coronavirus pneumonia novel coronavirus pneumonia patients were found to be infected only by 76/100000 in 5273 patients receiving androgen deprivation therapy. The 37161 patients with prostate cancer who did not receive androgen deprivation therapy had a new infection rate of 318/100000, while the infection rate of 79661 new cancer patients was also as high as 392/100000.

Epidemiological characteristics of sars-cov-2-infected prostate cancer patients treated with or without androgen deprivation therapy (ADT)

Novel coronavirus pneumonia novel coronavirus pneumonia novel coronavirus pneumonia has not been reported in all of the prostate cancer patients receiving androgen deprivation therapy. 18 of the patients with prostate cancer without androgen deprivation therapy have died of novel coronavirus (COVID-19,SARS-CoV-2) pneumonia. 57 of the other cancer patients have died of novel coronavirus (COVID-19,SARS-CoV-2) pneumonia.

Novel coronavirus pneumonia novel coronavirus pneumonia is more likely to cause serious complications or even death than women. What's more, androgen deprivation therapy may be used for prevention and treatment of novel coronavirus (COVID-19,SARS-CoV-2) pneumonia.

Can androgen deprivation therapy be promoted?

It is well known that androgen deprivation therapy can reduce the level of TMPRSS2 in prostate cancer patients, and some clinical evidences show that androgen deprivation therapy can also reduce the level of TMPRSS2 in other tissues of human body.

At present, a variety of androgen deprivation therapy has been approved for patients. For example, luteinizing hormone releasing hormone or LH-RH antagonist can reduce the level of testosterone in patients within 48 hours, and the treatment is also temporary. Once patients stop taking the medicine, their testosterone level will return to the previous level. Moreover, if the treatment time is less than one month, there will be no significant side effects.

Novel coronavirus pneumonia can promote novel coronavirus pneumonia infection and increase the severity of symptoms, researchers have suggested. Androgen deprivation therapy can help to treat and prevent novel coronavirus (COVID-19,SARS-CoV-2) infection.

Novel coronavirus pneumonia can also be prevented novel coronavirus pneumonia in a male who is not suffering from prostate cancer. For those with novel coronavirus pneumonia, androgen deprivation therapy can also be used to prevent the disease from deteriorating.

The researchers suggest that androgen deprivation therapy can be used in combination with other drugs that prevent the virus from multiplying and infecting human cells, or with drugs that interfere with the body's TMPRSS2 activity.

However, there are some limitations in this study. For example, because cancer patients often go to hospital for treatment, the risk of exposure to potential sources of infection is higher. Incidence rate of novel coronavirus pneumonia in cancer patients is what it can explain. Prostate cancer patients who use androgen deprivation therapy have a lower risk of exposure to potential sources of infection because they are mainly taking drugs at home.

In novel coronavirus pneumonia, Professor FabriceAndr e, editor in chief of oncology Yearbook, said: "we decided to publish this study because it provides a theoretical basis for uating androgen deprivation therapy for novel coronavirus (COVID-19,SARS-CoV-2) pneumonia infection. However, novel coronavirus pneumonia therapy is not available for direct diagnosis of the infection in patients with novel coronavirus (COVID-19,SARS-CoV-2) pneumonia. Therefore, we should not blindly use such drugs until prospective clinical trials confirm that they are effective.